A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis
Dimitrios Karagiannis1, Ilias Georgalas2, Ioannis Ladas2, Parikakis Eustratios1, Panagiotis Mitropoulos11Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece; 2Department of Ophthalmology, “G.Genimatas” General Hospital, Athens, GreeceAbstract: A 65-year-old lad...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fb8da5c43127472d9b2bbfd02f2f3194 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Dimitrios Karagiannis1, Ilias Georgalas2, Ioannis Ladas2, Parikakis Eustratios1, Panagiotis Mitropoulos11Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece; 2Department of Ophthalmology, “G.Genimatas” General Hospital, Athens, GreeceAbstract: A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.Keywords: idiopathic juxtafoveal retinal telangiectasis, ranibizumab, subretinal neovascularization |
|---|